Drug Profile

Seridopidine

Alternative Names: ACR343

Latest Information Update: 28 Jun 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Carlsson Research AB
Developer Saniona
Class Antiparkinsonians; Antipsychotics; Fluorobenzenes; Piperidines; Small molecules; Sulfones
Mechanism of Action Dopamine receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Gilles de la Tourette's syndrome; Parkinson's disease

Most Recent Events

28 Jun 2019 No recent reports of development identified for phase-I development in Gilles-de-la-Tourette's-syndrome in Sweden (PO)
28 Jun 2019 No recent reports of development identified for phase-I development in Parkinson's-disease in Sweden (PO)
31 May 2016 Saniona acquires ACR 343 from NeuroSearch

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com